Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Primary Plasma Cell Leukemia

Tundra lists 4 Primary Plasma Cell Leukemia clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06140966

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma

Gender: All

Ages: 18 Years - 70 Years

Updated: 2025-04-16

1 state

Multiple Myeloma
Primary Plasma Cell Leukemia
Extramedullary Multiple Myeloma
ACTIVE NOT RECRUITING

NCT05838131

Study of CT071 Injection in RRMM or PPCL

A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

Gender: All

Ages: 18 Years - Any

Updated: 2025-01-07

Multiple Myeloma
Primary Plasma Cell Leukemia
RECRUITING

NCT06636552

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

The primary objective of this study is to evaluate the efficacy of the alternating D-PAD/D-CVD induction regimen followed by D-CVD consolidation regimen and maintenance with daratumumab monotherapy, in terms of PFS, in the first-line setting of pPCL.

Gender: All

Ages: 18 Years - 80 Years

Updated: 2024-10-10

2 states

Primary Plasma Cell Leukemia
NOT YET RECRUITING

NCT06333509

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.

Gender: All

Ages: 18 Years - Any

Updated: 2024-03-27

Multiple Myeloma
Primary Plasma Cell Leukemia